Holen Sie sich die Stockscreener-App
7.5895
0.14%
-0.0105
Handel nachbörslich:
7.59
0.0005
+0.01%
Schlusskurs vom Vortag:
$7.60
Offen:
$7.56
24-Stunden-Volumen:
4,251
Relative Volume:
0.22
Marktkapitalisierung:
$29.75M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-24.77M
KGV:
-10.40
EPS:
-0.73
Netto-Cashflow:
$-17.36M
1W Leistung:
+1.19%
1M Leistung:
-9.76%
6M Leistung:
+5.41%
1J Leistung:
-22.56%
1-Tages-Spanne:
$7.24
$7.9487
1-Wochen-Bereich:
$7.20
$7.97
52-Wochen-Spanne:
$4.5601
$13.79
Mink Therapeutics Inc Stock (INKT) Company Profile
Firmenname
Mink Therapeutics Inc
Sektor
Branche
Telefon
212-994-8250
Adresse
149 FIFTH AVENUE, NEW YORK
Vergleichen Sie INKT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INKT
Mink Therapeutics Inc
|
7.5895 | 29.75M | 0 | -24.77M | -17.36M | -0.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Mink Therapeutics Inc Aktie (INKT) Neueste Nachrichten
MiNK Therapeutics to Announce Q1 2025 Financial Results and Host Conference Call on May 15th - Nasdaq
MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report - GlobeNewswire
Clinical-Stage Biotech MiNK Therapeutics Sets Q1 Earnings Date: Key iNKT Cell Therapy Updates Expected - Stock Titan
Geode Capital Management LLC Lowers Stock Position in MiNK Therapeutics, Inc. (NASDAQ:INKT) - Defense World
Learn to Evaluate (INKT) using the Charts - news.stocktradersdaily.com
Comparing Atyr PHARMA (NASDAQ:ATYR) and MiNK Therapeutics (NASDAQ:INKT) - Defense World
LIfT BioSciences appoints new CSO - Bdaily
LIfT BioSciences Appoints Mark A. Exley as Chief Scientific Officer - EIN News
ImmunityBio to Host Key Opinion Leader and Investor Meeting to Provide Updates on Clinical Programs and ANKTIVA Commercial Launch - Business Wire
(INKT) Trading Report - news.stocktradersdaily.com
Reviewing MiNK Therapeutics (NASDAQ:INKT) & Creative Medical Technology (NASDAQ:CELZ) - The AM Reporter
Where are the Opportunities in (INKT) - news.stocktradersdaily.com
HC Wainwright Issues Negative Forecast for INKT Earnings - Defense World
What is William Blair’s Forecast for INKT Q1 Earnings? - Defense World
What is William Blair’s Estimate for INKT Q1 Earnings? - Defense World
MiNK Therapeutics, Inc. (NASDAQ:INKT) Q4 2024 Earnings Call Transcript - Insider Monkey
MiNK Therapeutics (NASDAQ:INKT) Given Buy Rating at HC Wainwright - Defense World
MiNK Therapeutics Inc (INKT) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ... By GuruFocus - Investing.com Canada
MiNK Therapeutics Reports 2024 Progress and Financials - TipRanks
MiNK Therapeutics’ Earnings Call Highlights Strategic Gains - TipRanks
MiNK Therapeutics, Inc. SEC 10-K Report - TradingView
Earnings call transcript: Mink Therapeutics Q4 2024 reports reduced net loss - Investing.com
Mink Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
MiNK Therapeutics Reports Fourth Quarter & Full Year 2024 Results and Highlights Business Progress - GlobeNewswire
MiNK Therapeutics Reports 2024 Financial Results and Highlights Clinical Advancements in iNKT Cell Therapies - Nasdaq
MiNK Therapeutics reports Q4 EPS (62c), consensus (50c) - TipRanks
Earnings Scheduled For March 18, 2025 - Benzinga
AGENUS INC SEC 10-K Report - TradingView
(INKT) Technical Pivots with Risk Controls - Stock Traders Daily
Mink Therapeutics Inc expected to post a loss of 50 cents a shareEarnings Preview - TradingView
MiNK Therapeutics (INKT) Projected to Post Earnings on Tuesday - Defense World
New Strong Buy Stocks for July 11th - MSN
The Future of Refractory Multiple Myeloma Therapy: 75+ - openPR
MiNK Therapeutics, Inc. to Announce Fourth Quarter and Year End 2024 Financial Results on March 18th - Nasdaq
MiNK Therapeutics to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report - GlobeNewswire
When Will MiNK Therapeutics Reveal Its 2024 Financial Performance? - StockTitan
What is HC Wainwright’s Estimate for INKT Q1 Earnings? - Defense World
Brokers Set Expectations for INKT FY2029 Earnings - Defense World
Agenus Reports Impact of Key Immuno-Oncology Data Presented at Leading Medical Conferences and Peer-Reviewed Publications - Business Wire
MiNK Therapeutics stock target soars to $35 at H.C. Wainwright By Investing.com - Investing.com South Africa
MiNK Therapeutics stock target soars to $35 at H.C. Wainwright - Investing.com India
MiNK Therapeutics presents allo-iNKTs combination data in 2L gastric cancer - TipRanks
MiNK Therapeutics Presents First-in-Kind Allo-iNKTs - GlobeNewswire
MiNK Therapeutics Presents Promising Data from Phase 2 Study of Allo-iNKT Cell Therapy AgenT-797 at AACR Meeting - Nasdaq
MiNK Therapeutics Presents First-in-Kind Allo-iNKTs Combination Data in 2L Gastric Cancer at AACR IO Annual Meeting - The Manila Times
Can This Novel Cancer Therapy Revolutionize Gastric Cancer Treatment? New Clinical Data Reveals Answer - StockTitan
How the (INKT) price action is used to our Advantage - news.stocktradersdaily.com
MiNK Therapeutics regains Nasdaq compliance By Investing.com - Investing.com Nigeria
MiNK Therapeutics Announces Regained Compliance With Nasdaq Listing Requirements - Nasdaq
MiNK Therapeutics regains Nasdaq compliance - Investing.com India
Tango Therapeutics to Present at Three Upcoming Investment Bank Conferences - The Manila Times
Finanzdaten der Mink Therapeutics Inc-Aktie (INKT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.39%
3.66%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):